December 16, 2025 Is the era within which a TURP was performed associated with differences in reoperation rates, specific surgical side effects, or the requirement for BPH medicat ...
Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...
At the 2025 UCSF-UCLA PSMA Conference, Jeremie Calais provides an overview of ongoing PSMA radiopharmaceutical therapy trials across different disease stages. He reviews major phase 3 trials in ...
At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...
Autonomic nerves and ganglia that affect bladder sensation and detrusor contractility are present below the proximal urethra and trigone. Radiofrequency energy has been shown to potentially ...
Read the Full Video Transcript Neeraj Agarwal: Welcome to another UroToday episode. Here we have Dr. Umang Swami, who is a faculty in oncology division at the Huntsman Cancer Institute at the ...
Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the ...
Comparing EMBARK vs EAU High-Risk Biochemical Recurrence Criteria in Prostate Cancer - Ugo Falagario
Zachary Klassen speaks with Ugo Falagario about identifying high-risk biochemical recurrence (BCR) after prostate cancer treatment. Dr. Falagario discusses findings from an analysis of the Stockholm-0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback